Table 1.

Growth inhibition of trifluorothymidine (TFT) and docetaxel in colorectal cancer cells: combination analysis of various treatment schedules of TFT combined with docetaxel

Cell line	Growth inhibition (IC50)		Combination index
	TFT (µmol/L)	Docetaxel (nmol/L)	Simultaneous	pTFT	pDoc
WiDR	3.2 ± 0.3	1.7 ± 0.3	1.95 ± 0.13	>10	0.62 ± 0.04
Colo320	0.6 ± 0.1	16 ± 1.4	0.76 ± 0.18	0.77 ± 0.10	0.80 ± 0.20

IC₅₀ values were estimated from graphs (Fig. 1) and are given in means of at least three to five independent experiments ± SEM. Average combination index (CI) values were calculated from the fraction affected (FA) from data points with a FA of 0.5, 0.75, and 0.9. CI values < 0.9 indicate synergy; CI = 0.9–1 mean additive; CI > 1.1 means antagonism. Values represent mean CI values ± SEM of three to four independent experiments. pDoc, pre‐exposed to docetaxel; pTFT, pre‐exposed to trifluorothymidine; TFT, trifluorothymidine. IC₅₀, inhibitory concentration of 50%.